← Eichor
Study identifier: NCT02097706 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Novel Drug for Borderline Personality Disorder

Condition: Borderline Personality Disorder  ·  Sponsor: The Alfred

PhasePhase 2
Planned participants150
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

Borderline Personality Disorder (BPD) is one of the most prevalent psychiatric disorders with high morbidity and mortality. It affects the lives of millions worldwide and is often highly incapacitating, leading to significant psychosocial dysfunction. Moreover, nearly all patients have experienced suicidal ideation and about 10% actually commit suicide, a rate almost 50 times higher than in the general population. Mostly young women are at greater risk for the disorder and are three times more likely to be diagnosed with BPD than men. BPD aetiology is complex and could be explained by both biological and environmental factors. Among the environmental factors, sexual or physical abuse, parental divorce, loss or illnesses are identified as the most common ones. These factors can induce dysfunctional behaviours, which might cause emotional dysregulation, high impulsivity and frequent self- injurious behaviour. However, there are no pharmacologic interventions that are known to be specifically effective to treat BPD. Therapeutic options for this devastating disorder is still far from adequate for treating acute illness episodes, relapses, and recurrences and in restoring premorbid functioning. In addition, some patients are unable to tolerate existing therapies for BPD, which leads to either frequent changes in medications or to non-adherence. Therefore there is an urgent need for the development of more rapidly effective treatments for BPD. A growing body of evidence suggests…

This description comes directly from the study's public registry record.

Talk to the study team

Jayashri Kulkarni AM, MBBS,MPM,FRANZCP,PhD  ·  +61 3 90766924  ·  j.kulkarni@alfred.org.au

Anthony deCastella, DipAppSci,BA,MA  ·  +61 3 90766564  ·  a.decastella@alfred.org.au

Always discuss trial participation with your own doctor first.

Locations (1)

Monash Alfred Psychiatry Research CentreMelbourne, Victoria, AustraliaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT02097706